OC
TPTX

Oppenheimer & Co’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Oppenheimer & Co’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,443
Closed -$355K – 1616
2021
Q4 		$355K Sell
7,443
-383
-5% -$17.1K 0.01% 1154
2021
Q3 		$520K Buy
7,826
+2,316
+42% +$165K 0.01% 1005
2021
Q2 		$430K Buy
+5,510
New +$407K 0.01% 1100

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Oppenheimer & Co's TPTX Position: Q1 2022 in Review

Oppenheimer & Co sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 7,443 shares — an estimated $355K sold.

Oppenheimer & Co first reported a position in TPTX in Q2 2021 and held it in 3 quarters. The position peaked at $520K in Q3 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Oppenheimer & Co reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 7,443 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $355K.
  • Oppenheimer & Co first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Oppenheimer & Co's Turning Point Therapeutics, Inc. Common Stock position peaked at $520K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.